M Gauthe
Overview
Explore the profile of M Gauthe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peyrottes A, Roupret M, Fiard G, Fromont G, Barret E, Brureau L, et al.
Prog Urol
. 2023 Oct;
33(15-16):956-965.
PMID: 37805291
Prostate cancer (PCa) is a public health issue. The diagnostic strategy for PCa is well codified and assessed by digital rectal examination, PSA testing and multiparametric MRI, which may or...
2.
Baboudjian M, Gauthe M, Barret E, Brureau L, Rocchi P, Crehange G, et al.
Prog Urol
. 2023 Jan;
32(6S1):6S43-6S53.
PMID: 36719646
Introduction: The aim of this narrative review conducted by the Prostate Cancer Committee of the French Association of Urology (CC-AFU) was to provide an update on the current evidence for...
3.
Lasserre M, Sargos P, Barret E, Beauval J, Brureau L, Crehange G, et al.
Prog Urol
. 2023 Jan;
32(6S1):6S33-6S42.
PMID: 36719645
Patients treated by radical prostatectomy (RP) for localized prostate cancer (PCa) may experience biochemical recurrence (BCR) in approximately 30% of cases. Recently, advances in imaging modalities and in particular Positron-Emission...
4.
Ploussard G, Roubaud G, Barret E, Beauval J, Brureau L, Crehange G, et al.
Prog Urol
. 2022 Nov;
32(15):1373-1419.
PMID: 36400484
Objective: The objective of the French Urology Association Cancer Committee is to propose an update of the recommendations for the management of prostate cancer. Methods: A systematic review of the...
5.
Ploussard G, Fiard G, Barret E, Brureau L, Crehange G, Dariane C, et al.
Prog Urol
. 2022 Nov;
32(15):1275-1372.
PMID: 36400483
Objective: The objective of the French Urology Association Cancer Committee is to propose an update of the recommendations for the diagnosis and management of prostate cancer (PC). Methods: A systematic...
6.
Baboudjian M, Beauval J, Barret E, Brureau L, Crehange G, Dariane C, et al.
Prog Urol
. 2022 Jun;
32(10):623-634.
PMID: 35644728
Introduction: The risk of recurrence is increased in localized high-risk prostate cancer (PCa). The implementation of an appropriate diagnostic and therapeutic strategy is essential. The objective of this update by...
7.
Ploussard G, Beauval J, Mathieu R, Barret E, Brureau L, Crehange G, et al.
Prog Urol
. 2022 Feb;
32(3):155-164.
PMID: 35125317
Introduction: Current therapeutic developments in prostate cancer (PCa) tend to increasingly personalize the treatment strategy, in particular as a function of tumor genomics. Recently, poly ADP-ribose polymerase (PARPi) inhibitors have...
8.
Tamzali Y, Jamme M, Bottet F, Gauthe M, Rondeau E, Pialoux G, et al.
Infect Dis Now
. 2020 Oct;
51(2):209-211.
PMID: 33007403
No abstract available.
9.
Ohnona J, Nataf V, Gauthe M, Balogova S, Belissant Benesty O, Zhang-Yin J, et al.
Neoplasma
. 2018 Dec;
66(1):140-148.
PMID: 30509093
Despite their relative quiescence, pancreatic neuro-endocrine tumors (pNET) can correspond to various presentations and outcomes. Several prognostic factors have been identified, including maximal standardized uptake value of the most intense...
10.
Gauthe M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau A, et al.
Prog Urol
. 2017 Jun;
27(8-9):474-481.
PMID: 28576423
Introduction: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients...